Page last updated: 2024-08-23

etoposide and Genetic Diseases

etoposide has been researched along with Genetic Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ambra, R; Antonelli, A; Chessa, L; Elli, R; Marcucci, L; Petrinelli, P	1
Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G	1

Other Studies

2 other study(ies) available for etoposide and Genetic Diseases

Article	Year
Effects of topoisomerase II inhibition in lymphoblasts from patients with progeroid and "chromosome instability" syndromes. Cancer genetics and cytogenetics, 1996, Volume: 87, Issue:2 Topics: Ataxia Telangiectasia; Bleomycin; Bloom Syndrome; Cell Line; Cockayne Syndrome; DNA Damage; Etoposide; Genetic Diseases, Inborn; Humans; Lymphocytes; Topoisomerase II Inhibitors; Werner Syndrome; Xeroderma Pigmentosum	1996
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone marrow transplantation, 2001, Volume: 28, Issue:8 Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2001

Article

Year

Effects of topoisomerase II inhibition in lymphoblasts from patients with progeroid and "chromosome instability" syndromes.

Cancer genetics and cytogenetics, 1996, Volume: 87, Issue:2

Topics: Ataxia Telangiectasia; Bleomycin; Bloom Syndrome; Cell Line; Cockayne Syndrome; DNA Damage; Etoposide; Genetic Diseases, Inborn; Humans; Lymphocytes; Topoisomerase II Inhibitors; Werner Syndrome; Xeroderma Pigmentosum

1996

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

Bone marrow transplantation, 2001, Volume: 28, Issue:8

Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2001